American Society of Clinical Oncology

SHERPA: White

People

  1. Zelenetz
    Zelenetz
  2. Noy
    Noy
  3. Panageas
    Panageas
  4. Scheinberg
    Scheinberg
  5. Horwitz
    Horwitz
  6. Palomba
    Palomba
  7. Schwartz
    Schwartz

Groups

  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Lymphoma (4)
  5. Adult Leukemia (3)
  6. Nursing (3)
  7. Population Sciences Research Program (3)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  9. Biostatistics Service (2)
  10. Epidemiology and Biostatistics (2)
Search Within
  1. "Lymphoma"
  2. "Mark Heaney"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (1)
Groups
  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Lymphoma (4)
  5. Adult Leukemia (3)
  6. Nursing (3)

More Groups

People
  1. Mark Heaney (4)
  2. Andrew Zelenetz (3)
  3. Joseph Jurcic (3)
  4. Nicole Lamanna (3)
  5. Peter Maslak (3)
  6. Alison Gencarelli (2)

More People

Years
  1. 2012 (1)
  2. 2009 (1)
  3. 2006 (2)
Publications
  1. Journal of Clinical Oncology (4)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A new paradigm in CLL: Minimizing toxicity by using the minimum effective dose (MED) of lenalidomide for older patients with CLL
    Meeting Abstract

    Lamanna, N.; Heaney, M. L.; Maslak, P. G.; Jurcic, J. G.; Rosenblat, T. L.; Noy, A.; Palomba, M. L.; Weiss, M. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    Journal Article

    Lamanna, N.; Jurcic, J. G.; Noy, A.; Maslak, P.; Gencarelli, A. N.; Panageas, K. S.; Heaney, M. L.; Brentjens, R. J.; Golde, D. W.; Scheinberg, D. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Journal Article

    O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; Macgregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save